Safety assessment of raloxifene over eight years in a clinical trial setting

Current Medical Research and Opinion

Volumn 21, Issue 9, 2005, Pages 1441-1452

  Martino, Silvana ^a   Disch, Damon ^b   Dowsett, Sherie A ^b   Keech, Cheryl A ^b   Mershon, John L ^b  

^a Angeles Clinic and Research Institute   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse event; Raloxifene; Safety; Trial

Indexed keywords

PLACEBO; RALOXIFENE;

AGED; BONE DENSITY; BREAST CANCER; CANCER; CANCER INCIDENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FLU LIKE SYNDROME; HEART INFARCTION; HOT FLUSH; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MUSCLE CRAMP; OVARY CANCER; POLLAKISURIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD VESSEL OCCLUSION; SKIN CANCER; STROKE; UTERUS CANCER; UTERUS SARCOMA; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; BONE DENSITY; CARDIOVASCULAR SYSTEM; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RALOXIFENE; SAFETY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VENOUS THROMBOSIS;

EID: 25444486711     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X61839     Document Type: Conference Paper

References (25)

1. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
2. US prescribing information, Eli Lilly and Company, Indianapolis, IN, 2003
3. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
4. Cummings SR, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999:281;2189-97.
5. Erratum in: JAMA 1999;282:2124
6. Cauley J, Norton L, Lippman ME, et al. Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-year Results from the MORE Trial. Breast Cancer Res Treat 2001;65:125-34
7. Martino S, Cauley JA, Barrett-Connor E, et al. Invasive breast cancer risk reduction in postmenopausal women with osteoporosis treated with raloxifene for 8 years: Results from the Continuing Outcomes Relevant to Evista trial. J Natl Cancer Inst 2004;96:1751-61
8. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73
9. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44
10. Lu Y, Cohen F, Lakshmanan M. Characterization of hot flashes during raloxifene therapy: analyses of adverse event reports from an integrated placebo-controlled clinical trial database. Menopause 1998;5:282
11. Grady D, Ettinger B, Moscarelli E, et al. Safety and Adverse Effects Associated with Raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol 2004;104:837-44
12. Cohen FJ, Watts S, Shah A, et al. Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000;95:104-10
13. Neven P, Goldstein SR, Ciaccia AV, et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 2002;85:388-90
14. Yaffe K, Krueger K, Sarkar S, et al. Cognitive Function in Postmenopausal Women Treated with Raloxifene. N Engl J Med 2001;344:1207-13
15. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57
16. International Conference on Harmonisation. International Conference on Harmonisation. 2004
17. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception. J Clin Epidemiol 1995;48:1513-47
18. Carlin B, Gelfand A, Smith A. Hierarchical Bayesian analysis of change-point problems. J Roy Statistical Society, Series C 1992;41:389-405
19. Congdon P. Normal linear regression, general linear models and log-linear models. Bayesian statistical modeling. Wiley, 2001, pp. 118-21
20. Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial. J Bone Miner Res 2004;19:1270-5
21. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-5
22. Goldstein SR, Johnson S, Watts NB, et al. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause 2005;12:160-4
23. Jarkova NB, Martenyi F, Masanauskaite D, et al. Mood effect of raloxifene in postmenopausal women. Maturitas 2002;42:71-5
24. Nickelsen T, Lufkin EG, Riggs BL, et al. III. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999;24:115-28
25. Brown EG. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Safety 2003;26:145-58